 Vir Biotechnology obliterated expectations for its Covid drug in the third quarter, and Vir stock leaped above its 200-day line. The post Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth appeared first on Investors Business Daily. 